FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327606489> ?p ?o ?g. }

• W4327606489 endingPage "1984" @default.
• W4327606489 startingPage "1974" @default.
• W4327606489 abstract "Celecoxib has been used to treat hip discomfort and functional difficulties associated with osteonecrosis of the femoral head (ONFH), although significant adverse reactions often follow long-term use. Extracorporeal shock wave therapy (ESWT) can delay the progression of ONFH, alleviate the pain and functional limitations it causes, and avoid the adverse effects of celecoxib.To investigate the effects of individual ESWT, a treatment alternative to the use of celecoxib, in alleviating pain and dysfunction caused by ONFH.This was a randomized, controlled, double-blinded, non-inferiority trial. We examined 80 patients for eligibility in this study; 8 patients were excluded based on inclusion and exclusion criteria. A total of 72 subjects with ONFH were randomly assigned to group A (n = 36; celecoxib + alendronate + sham-placebo shock wave) or group B (n = 36; individual focused shock wave [ESWT based on magnetic resonance imaging three-dimensional (MRI-3D) reconstruction] + alendronate). The outcomes were assessed at baseline, at the end of treatment, and at an 8-wk follow-up. The primary outcome measure was treatment efficiency after 2 wk of intervention using the Harris hip score (HHS) (improvement of 10 points or more from the baseline was deemed sufficient). Secondary outcome measures were post-treatment HHS, visual analog scale (VAS), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores.After treatment, the pain treatment efficiency of group B was greater than that of group A (69% vs 51%; 95%CI: 4.56% to 40.56%), with non-inferiority thresholds of -4.56% and -10%, respectively. Furthermore, the HHS, WOMAC, and VAS scores in group B dramatically improved during the follow-up period as compared to those in group A (P < 0.001). After therapy, the VAS and WOMAC in group A were significantly improved from the 2nd to 8th wk (P < 0.001), although HHS was only significantly altered at the 2 wk point (P < 0.001). On the 1st d and 2nd wk after treatment, HHS and VAS scores were different between groups, with the difference in HHS lasting until week 4. Neither group had severe complications such as skin ulcer infection or lower limb motor-sensory disturbance.Individual shock wave therapy (ESWT) based on MRI-3D reconstruction was not inferior to celecoxib in managing hip pain and restrictions associated with ONFH." @default.
• W4327606489 created "2023-03-17" @default.
• W4327606489 creator A5016518498 @default.
• W4327606489 creator A5023973442 @default.
• W4327606489 creator A5037960195 @default.
• W4327606489 creator A5047999340 @default.
• W4327606489 creator A5068740176 @default.
• W4327606489 creator A5082259132 @default.
• W4327606489 date "2023-03-26" @default.
• W4327606489 modified "2023-09-25" @default.
• W4327606489 title "Effects of individual shock wave therapy <i>vs</i> celecoxib on hip pain caused by femoral head necrosis" @default.
• W4327606489 cites W1143976663 @default.
• W4327606489 cites W1585339727 @default.
• W4327606489 cites W1906270204 @default.
• W4327606489 cites W1989121656 @default.
• W4327606489 cites W1997259982 @default.
• W4327606489 cites W1999390827 @default.
• W4327606489 cites W2003104554 @default.
• W4327606489 cites W2003745782 @default.
• W4327606489 cites W2015962884 @default.
• W4327606489 cites W2021075645 @default.
• W4327606489 cites W2030920550 @default.
• W4327606489 cites W2034836185 @default.
• W4327606489 cites W2041741017 @default.
• W4327606489 cites W2057903469 @default.
• W4327606489 cites W2067581992 @default.
• W4327606489 cites W2083464592 @default.
• W4327606489 cites W2105341770 @default.
• W4327606489 cites W2146447031 @default.
• W4327606489 cites W2148381133 @default.
• W4327606489 cites W2155504662 @default.
• W4327606489 cites W2165039186 @default.
• W4327606489 cites W2170349508 @default.
• W4327606489 cites W2223529699 @default.
• W4327606489 cites W2484114009 @default.
• W4327606489 cites W2522474170 @default.
• W4327606489 cites W2893512343 @default.
• W4327606489 cites W2922201903 @default.
• W4327606489 cites W2998134613 @default.
• W4327606489 cites W2999292999 @default.
• W4327606489 cites W3007683053 @default.
• W4327606489 cites W3144540946 @default.
• W4327606489 cites W3189947036 @default.
• W4327606489 cites W3201359819 @default.
• W4327606489 cites W4205783739 @default.
• W4327606489 cites W4211107121 @default.
• W4327606489 cites W4224222603 @default.
• W4327606489 cites W4224282276 @default.
• W4327606489 cites W4226229667 @default.
• W4327606489 cites W4254316526 @default.
• W4327606489 cites W3083564720 @default.
• W4327606489 doi "https://doi.org/10.12998/wjcc.v11.i9.1974" @default.
• W4327606489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36998970" @default.
• W4327606489 hasPublicationYear "2023" @default.
• W4327606489 type Work @default.
• W4327606489 citedByCount "0" @default.
• W4327606489 crossrefType "journal-article" @default.
• W4327606489 hasAuthorship W4327606489A5016518498 @default.
• W4327606489 hasAuthorship W4327606489A5023973442 @default.
• W4327606489 hasAuthorship W4327606489A5037960195 @default.
• W4327606489 hasAuthorship W4327606489A5047999340 @default.
• W4327606489 hasAuthorship W4327606489A5068740176 @default.
• W4327606489 hasAuthorship W4327606489A5082259132 @default.
• W4327606489 hasBestOaLocation W43276064891 @default.
• W4327606489 hasConcept C126322002 @default.
• W4327606489 hasConcept C141071460 @default.
• W4327606489 hasConcept C14184104 @default.
• W4327606489 hasConcept C142724271 @default.
• W4327606489 hasConcept C168563851 @default.
• W4327606489 hasConcept C197934379 @default.
• W4327606489 hasConcept C204787440 @default.
• W4327606489 hasConcept C27081682 @default.
• W4327606489 hasConcept C2776164576 @default.
• W4327606489 hasConcept C2776211809 @default.
• W4327606489 hasConcept C2776467144 @default.
• W4327606489 hasConcept C2777572544 @default.
• W4327606489 hasConcept C2779100257 @default.
• W4327606489 hasConcept C2779286237 @default.
• W4327606489 hasConcept C3020453552 @default.
• W4327606489 hasConcept C71924100 @default.
• W4327606489 hasConceptScore W4327606489C126322002 @default.
• W4327606489 hasConceptScore W4327606489C141071460 @default.
• W4327606489 hasConceptScore W4327606489C14184104 @default.
• W4327606489 hasConceptScore W4327606489C142724271 @default.
• W4327606489 hasConceptScore W4327606489C168563851 @default.
• W4327606489 hasConceptScore W4327606489C197934379 @default.
• W4327606489 hasConceptScore W4327606489C204787440 @default.
• W4327606489 hasConceptScore W4327606489C27081682 @default.
• W4327606489 hasConceptScore W4327606489C2776164576 @default.
• W4327606489 hasConceptScore W4327606489C2776211809 @default.
• W4327606489 hasConceptScore W4327606489C2776467144 @default.
• W4327606489 hasConceptScore W4327606489C2777572544 @default.
• W4327606489 hasConceptScore W4327606489C2779100257 @default.
• W4327606489 hasConceptScore W4327606489C2779286237 @default.
• W4327606489 hasConceptScore W4327606489C3020453552 @default.
• W4327606489 hasConceptScore W4327606489C71924100 @default.
• W4327606489 hasIssue "9" @default.
• W4327606489 hasLocation W43276064891 @default.

• next